OVERVIEW
A six-month result is notable, but it is not the same as ‘treating 0.51 D of myopia’
Spectacle lenses for childhood myopia are moving beyond simple vision correction toward optical designs intended to slow progression.
On September 22, 2026, EssilorLuxottica announced six-month interim results from an ongoing two-year randomized, double-masked clinical trial in China. According to the company, Stellest 2.0 showed an average treatment effect versus single-vision lenses of 0.51 D for spherical-equivalent myopia progression and 0.21 mm for axial elongation.
Those numbers are differences in progression between groups over the same period. They should not be read as ‘0.51 D of myopia was treated in six months.’
01 · INTERIM RESULT
These are six-month interim data, not the final two-year result
EssilorLuxottica says the interim analysis included 62 children in the Stellest 2.0 group and 58 in the single-vision group in an ongoing trial in Guangzhou, China.
At six months, the reported between-group effects were 0.51 D for spherical-equivalent progression and 0.21 mm for axial elongation.
The company compared these figures with 0.53 D and 0.23 mm previously reported at 12 months in a separate first-generation Stellest trial. That is an indirect comparison across different studies, not a randomized head-to-head test of generation 1 versus 2.0.
02 · AXIAL LENGTH
Myopia-control studies look at both refraction and axial length
Changes in spherical-equivalent refraction are important, but axial length is also a central outcome in childhood myopia research.
Axial length measures the front-to-back length of the eye, so modern spectacle-lens trials commonly report both refractive progression and axial elongation.
The Stellest 2.0 interim announcement reported both outcomes.
03 · EXISTING EVIDENCE
Two-year randomized evidence already exists for HAL spectacle lenses
A 2022 double-masked randomized trial in China analyzed 157 children. Over two years, the HAL group had 0.80 D less myopia progression and 0.35 mm less axial elongation than the single-vision group.
A separate US randomized trial published online in JAMA Ophthalmology in August 2026 randomized 159 children, with 135 completing the 24-month assessment. At 24 months, the adjusted between-group difference was 0.64 D for cycloplegic spherical equivalent and 0.24 mm for axial length.
These studies add evidence for the category, but they do not imply that every myopia-control spectacle design performs identically.
04 · DESIGN COMPETITION
‘Myopia-control spectacle lens’ is a category, not a single optical design
Spectacle-based myopia control now includes several optical approaches, including highly aspherical lenslets, multi-segment designs and dual-index aspherical lenslets.
A 2025 randomized, double-masked DIAL trial recruited 80 children aged 8 to 13 and used axial elongation as a main outcome.
Percentage-reduction claims from different products should not be ranked as if they came from one trial. Age, baseline refraction, control-group progression, wearing time, follow-up length and analysis methods can all change the percentage.
05 · OPTICAL STORE
For optical stores, fabrication, fitting and longitudinal records become more important
Myopia-control spectacles are not a category where the product name alone tells the whole story.
Optical stores can repeatedly verify whether the prescribed spectacles remain stable on the face, whether fitting has changed, whether lenses were fabricated in the ordered position, and whether the physical spectacles are being worn as intended.
Axial-length measurement and cycloplegic refraction are medical evaluations when clinically indicated. Optical stores should not substitute for those assessments; their strength is maintaining accurate fabrication, fitting and wear records and connecting them with examination information provided by the patient or eye-care team.
06 · HOW TO READ
Read the study conditions before the headline number
Useful questions include: What ages were studied? What was the baseline prescription range? Was the comparator a conventional single-vision lens? Was cycloplegic refraction used? Was axial length measured? How was wearing time tracked? How long was follow-up? Is this an interim analysis, a final paper, or a manufacturer announcement?
A single efficacy number without those conditions can make the evidence look more comparable than it really is.
WHAT THIS MEANS
Competition is shifting from ‘does it work?’ to ‘which optical design works consistently, and over what time frame?’
The most important part of the Stellest 2.0 announcement is not a single 0.51 D or 0.21 mm number. It is the sign that myopia-control spectacle lenses are becoming a competition in optical design, early follow-up effects and long-term evidence.
At the same time, these are six-month interim findings from an ongoing trial and were released by the manufacturer. Long-term durability of the effect and any superiority over the first generation cannot be established until fuller results and peer-reviewed reporting are available.
Authorization, launch and commercial availability can differ by country, so current local regulatory and market status should be checked separately.
GLANOS Brief looks at study design, comparators, measurement endpoints and the practical conditions optical stores need to watch—not only the product headline.
Sources & References
Product claims, study results and clinical context in this article were checked against the company’s official materials and the academic sources listed below.
- EssilorLuxotticaEssilorLuxottica unveils the best six-month treatment effects ever reported across its clinical studies on Essilor Stellest lenses
- JAMA Ophthalmology · 2022Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial
- JAMA Ophthalmology · 2026Spectacle Lenses With Highly Aspherical Lenslets for Myopia Control: A Randomized Clinical Trial
- PubMed · Ophthalmology Science · 2025Myopia Control Efficacy of Spectacle Lenses with Dual-Index Aspherical Lenslets: A 1-Year Randomized Clinical Trial
This article is for understanding eyewear-industry and vision-science developments. It does not replace individual diagnosis, treatment or prescribing.